GIN Exam 1

Prevacid

PPI

Inhibits gastric parietal cell hydrogen-potassium ATPase

Headache, diarrhea, abdominal pain, nausea, flatulence, long term use can lead to osteoporosis

15-20 mg PO qD

Dexilant

PPI

Inhibits gastric parietal cell hydrogen-potassium ATPase

Headache, diarrhea, abdominal pain, nausea, flatulence, increased risk of osteoporosis

Initial: 60 mg PO qD, maintenance: 30 mg PO qD

Protonix

PPI

Inhibits gastric parietal cell hydrogen-potassium ATPase

Diarrhea, headache, abdominal pain, nausea, flatulence, dizziness, vertigo, myalgia, long term use causes bone loss

20 mg PO/IV qD

Prilosec

PPI

Inhibits gastric parietal cell hydrogen-potassium ATPase

Diarrhea, headache, abdominal pain, nausea, flatulence, dizziness, rash, upper respiratory infection, long term use causes bone loss

20 mg PO qD

Nexium

PPI

Inhibits gastric parietal cell hydrogen-potassium ATPase

Diarrhea, headache, abdominal pain, nausea, vomiting, flatulence, dizziness, long term use causes bone loss

20-40 mg PO qD

Pepcid

H2 antagonist

Antagonizes H2 histamine receptors

Dizziness, headache, taste changes, constipation, diarrhea

20-40 mg PO qD

Advil, Motrin

NSAID

Inhibits COX, reducing prostaglandin and thromboxane synthesis

Dyspepsia, nausea, abdominal pain, constipation, headache, drowsiness, photosensitivity

300-800 mg TID or QID

ASA/NSAID induced asthma, 2nd/3rd trimester of pregnancy, CABG surgery

May increase risk of CV thrombotic events, may increase risk of fatal GI events such as GI bleed, ulceration, proliferation

Mobic

NSAID

Inhibits COX, reducing prostaglandin and thromboxane synthesis

Dyspepsia, nausea, abdominal pain, dizziness, headache, rash, contipation, edema, GI bleed

7.5-15 mg PO qD

ASA/NSAID allergy, 2nd/3rd trimester of pregnancy

May increase risk of CV thrombotic events, may increase risk of fatal GI events such as GI bleed, ulceration, and proliferation

Naprosyn, Naprelan

NSAID

Inhibits COX, reducing prostaglandin and thromboxane synthesis

Dyspepsia, nausea, abdominal pain, constipation, drowsiness, photosensitivity, GI bleed

IR/DR: 250-500 mg PO q12h, ER: 750-1000 mg PO qD

ASA/NSAID induced asthma, 2nd/3rd trimester of pregnancy, CABG surgery

May increase risk of CV thrombotic events, may increase risk of fatal GI events such as GI bleeds, ulceration, and proliferation

Celebrex

NSAID

Selectively inhibits COX-2, reducing prostaglandin synthesis

Headache, diarrhea, nausea, vomiting, peripheral edema, photosensitivity, GI bleed

100-200 mg PO qD or BID

Hypersensitivity to sulfonamides, 2nd/3rd trimester of pregnancy

May increase risk of CV thrombotic events, may increase risk of fatal GI events such as GI bleed, ulceration, proliferation

Voltaren, Cambia, Catafiam

NSAID

Inhibits COX, reducing prostaglandin and thromboxane synthesis

Dyspepsia, vomiting, headache, dizziness, rash, drowsiness, fluid retention, GI bleed

DR: 50 mg PO BID or TID, ER: 100 mg PO qD

ASA/NSAID allergy, 2nd/3rd trimester of pregnancy

May increase risk of CV thrombotic events, may increase risk of fatal GI events such as GI bleed, ulceration, and proliferation

Toradol, Sprix

NSAID

Inhibits COX, reducing prostaglandin and thromboxane synthesis

GI bleed, perforation, ulcer, dyspepsia, nausea, abdominal pain, constipation, headache, drowsiness, photosensitivity

10 mg PO q4-6h PRN

Major surgery post-op, ASA/NSAID induced asthma, epidural or intrathecal use, CABG surgery

May increase risk of CV thrombotic events, may increase risk of fatal GI events such as GI bleed, ulceration, and proliferation; oral: up to 5 days treatment and only after parenteral use

False. Relevant in all environments including inpatient and outpatient as nutrition can be treatment for conditions

False

Routine patient screening with quick, simple, noninvasive way to identify risk factors in the general population

Recent and unintended weight loss, medications, medical conditions, diet and exercise history

Nutrition focused history, physical exam, anthropometric measurements, lab assessment

Nutrition intake, dietary habits, underlying pathology with nutritional impact, end-organ effects (weight changes), GI surgical history, medications, family history, alcohol or drug use, pregnancy status

Either directly or indirectly, indirect being side effects such as N/V

Vital signs, hair, skin, nails, eyes, nose, mouth, neck, abdomen, musculoskeletal system

Weight, height, waist circumference, head circumference, wrist circumference

Visceral proteins, nitrogen balance study, immune function test

Albumin, prealbumin, transferrin

Examines protein intake compared to protein use, generally only used with long term TPN use to ensure nutritional needs are being met

Total lymphocyte count, delayed cutaneous hypersensitivity

Consequence of nutrient imbalance either undernutrition or overnutrition

Starvation-associated malnutrition, chronic disease related malnutrition, acute disease/injury related malnutrition

Protein, energy, single nutrient

Unintended weight loss, chronic/acute illness, socioeconomic factors, substance use, medications, absorption issues

Stimulants, chemo, antacids, sulfasalazine, metformin

Weight loss is secondary to decreased appetite

Weight loss secondary to N/V/diarrhea, also possible nutritional deficiencies

Thiamine deficiency

Folate deficiency

Vitamin B12 and folate deficiency

Malnutrition resulting from prolonged inadequate intake, absorption, or utilization of protein and energy

Inadequate food supply, anorexia, depression, malabsorptive syndromes

Inflammatory